The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Structure-Based Vaccine Antigen Design
Open accessAbstract
Enabled by new approaches for rapid identification and selection of human monoclonal antibodies, atomic-level structural information for viral surface proteins, and capacity for precision engineering of protein immunogens and self-assembling nanoparticles, a new era of antigen design and display options has evolved. While HIV-1 vaccine development has been a driving force behind these technologies and concepts, clinical proof-of-concept for structure-based vaccine design may first be achieved for respiratory syncytial virus (RSV), where conformation-dependent access to neutralization-sensitive epitopes on the fusion glycoprotein determines the capacity to induce potent neutralizing activity. Success with RSV has motivated structure-based stabilization of other class I viral fusion proteins for use as immunogens and demonstrated the importance of structural information for developing vaccines against other viral pathogens, particularly difficult targets that have resisted prior vaccine development efforts. Solving viral surface protein structures also supports rapid vaccine antigen design and application of platform manufacturing approaches for emerging pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The rapid and robust immunogenicity profile of the mRNA-1273 vaccine most likely results from an innovative structure-based vaccine antigen design,23 coupled with a potent lipid-nanoparticle delivery system, and the use of modified nucleotides that avoid early intracellular activation of interferon-associated genes.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Burden of Respiratory Syncytial Virus Infection in Young Children
Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., Auinger, P., Griffin, M. R., Poehling, K. A., Erdman, D. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804877 · Cited by 2,250
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
Kuhn, R. J., Zhang, W., Rossmann, M. G., Pletnev, S. V., Corver, J., Lenches, E. M., Jones, C. T., Mukhopadhyay, S., Chipman, P. R., Strauss, E. G., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00660-8 · Cited by 1,565
Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus
Glezen, W. P. (1986) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1986.02140200053026 · Cited by 1,517
The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution
Rey, F. A., Heinz, F. X., Mandl, C. W., Künz, C., & Harrison, S. C. (1995) · Nature · doi:10.1038/375291a0 · Cited by 1,439
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Self-citationImmunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073
Self-citationEfficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
Kapikian, A. Z., MITCHELL, R. H., Chanock, R. M., Shvedoff, R. A., & STEWART, C. E. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120954 · Cited by 1,035
Sanders, R. W., Derking, R., Cupo, A., Julien, J., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003618 · Cited by 937
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Kanekiyo, M., Wei, C., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W., Wang, L., & Nabel, G. J. (2013) · Nature · doi:10.1038/nature12202 · Cited by 887
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
Self-citationStructure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Self-citationCrystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer
Julien, J., Cupo, A., Sok, D., Stanfield, R. L., Lyumkis, D., Deller, M. C., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., et al. (2013) · Science · doi:10.1126/science.1245625 · Cited by 821
Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I. S., Wang, C., Chen, X., Longo, N. S., Louder, M. K., McKee, K., et al. (2011) · Science · doi:10.1126/science.1207532 · Cited by 797
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. (2013) · Science · doi:10.1126/science.1234150 · Cited by 770
Pre-fusion structure of a human coronavirus spike protein
Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2016) · Nature · doi:10.1038/nature17200 · Cited by 765
Self-citationYuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu, Y., Yan, J., Shi, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms15092 · Cited by 756
Rappuoli, R. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00119-3 · Cited by 725
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C., Kanekiyo, M., Kong, W., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 700
Self-citationCryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer
Lyumkis, D., Julien, J., de Val, N., Cupo, A., Potter, C. S., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., Carragher, B. O., et al. (2013) · Science · doi:10.1126/science.1245627 · Cited by 683
Computational Design of Self-Assembling Protein Nanomaterials with Atomic Level Accuracy
King, N. P., Sheffler, W., Sawaya, M. R., Vollmar, B. S., Sumida, J. P., André, I., Gonen, T., Yeates, T. O., & Baker, D. A. (2012) · Science · doi:10.1126/science.1219364 · Cited by 655
Antibodies, viruses and vaccines
Burton, D. R. (2002) · Nature Reviews Immunology · doi:10.1038/nri891 · Cited by 637
CHIN, J., Magoffin, R. L., Shearer, L. A., SCHIEBLE, J. H., & Lennette, E. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120957 · Cited by 630
RESPIRATORY VIRUS IMMUNIZATION
Fulginiti, V. A., Eller, J. J., Sieber, O. F., Joyner, J. W., Minamitani, M., & Meiklejohn, G. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120956 · Cited by 609
Accurate design of co-assembling multi-component protein nanomaterials
King, N. P., Bale, J. B., Sheffler, W., McNamara, D. E., Gonen, S., Gonen, T., Yeates, T. O., & Baker, D. A. (2014) · Nature · doi:10.1038/nature13404 · Cited by 560
Proof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555
Self-citationBinley, J. Μ., Sanders, R. W., Clas, B., Schülke, N., Master, A., Guo, Y., Kajumo, F., Anselma, D. J., Maddon, P. J., Olson, W. C., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.2.627-643.2000 · Cited by 533
Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
Walls, A. C., Tortorici, M. A., Bosch, B., Frenz, B., Rottier, P. J. M., DiMaio, F., Rey, F. A., & Veesler, D. (2016) · Nature · doi:10.1038/nature16988 · Cited by 533
Recovery of Cytopathogenic Agent from Chimpanzees with Goryza
Morris, J. A., Blount, R. E., & Savage, R. E. (1956) · Experimental Biology and Medicine · doi:10.3181/00379727-92-22538 · Cited by 531
CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein
Tripp, R. A., Jones, L. P., Haynes, L. M., Zheng, H., Murphy, P. M., & Anderson, L. J. (2001) · Nature Immunology · doi:10.1038/90675 · Cited by 457
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & Gregorio, E. D. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151960 · Cited by 449
Sanders, R. W., Vesanen, M., Schülke, N., Master, A., Schiffner, L., Kalyanaraman, R., Paluch, M. T., Berkhout, B., Maddon, P. J., Olson, W. C., et al. (2002) · Journal of Virology · doi:10.1128/jvi.76.17.8875-8889.2002 · Cited by 441
Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera
Ngwuta, J. O., Chen, M., Modjarrad, K., Joyce, M. G., Kanekiyo, M., Kumar, A., Yassine, H. M., Moin, S. M., Killikelly, A. M., Chuang, G., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4241 · Cited by 439
Self-citationRECOVERY FROM INFANTS WITH RESPIRATORY ILLNESS OF A VIRUS RELATED TO CHIMPANZEE CORYZA AGENT (CCA)
Chanock, R. M., Roizman, B., & Myers, R. M. (1957) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a119901 · Cited by 420
Walls, A. C., Tortorici, M. A., Frenz, B., Snijder, J., Li, W., Rey, F. A., DiMaio, F., Bosch, B., & Veesler, D. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3293 · Cited by 417
Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes
Kallewaard, N. L., Corti, D., Collins, P. J., Neu, U., McAuliffe, J. M., Benjamin, E., Wachter-Rosati, L., Palmer‐Hill, F. J., Yuan, A. Q., Walker, P. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.073 · Cited by 410
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions
de Alwis, R., Smith, S. A., Olivarez, N. P., Messer, W. B., Huynh, J., Wahala, W. M. P. B., White, L., Diamond, M., Baric, R. S., Crowe, J. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200566109 · Cited by 390
A Blueprint for HIV Vaccine Discovery
Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.09.008 · Cited by 385
Buchholz, U. J., Bukreyev, A. A., Yang, L., Lamirande, E. W., Murphy, B. R., Subbarao, K., & Collins, P. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403492101 · Cited by 385
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
Krarup, A., Truan, D., Furmanova-Hollenstein, P., Bogaert, L., Bouchier, P., Bisschop, I. J. M., Widjojoatmodjo, M. N., Zahn, R., Schuitemaker, H., McLellan, J. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9143 · Cited by 383
Self-citationSupersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
Kong, L., Lee, J. H., Doores, K. J., Murin, C. D., Julien, J., McBride, R., Liu, Y., Marozsan, A. J., Cupo, A., Klasse, P.-J., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2594 · Cited by 334
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
Joyce, M. G., Wheatley, A. K., Thomas, P. V., Chuang, G.-Y., Soto, C., Bailer, R. T., Druz, A., Georgiev, I. S., Gillespie, R. A., Kanekiyo, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.043 · Cited by 333
Self-citationFalsey, A. R., McElhaney, J. E., Beran, J., van Essen, G. A., Duval, X., Esen, M., Galtier, F., Gervais, P., Hwang, S., Kremsner, P. G., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit839 · Cited by 298
Understanding and learning from the success of prophylactic human papillomavirus vaccines
Schiller, J. T., & Lowy, D. R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2872 · Cited by 295
Lo, M. S., Brazas, R. M., & Holtzman, M. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.14.9315-9319.2005 · Cited by 284
Elicitation of structure-specific antibodies by epitope scaffolds
Ofek, G., Guenaga, F. J., Schief, W. R., Skinner, J., Baker, D., Wyatt, R., & Kwong, P. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004728107 · Cited by 278
Degrees of maturity: the complex structure and biology of flaviviruses
Pierson, T. C., & Diamond, M. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.02.011 · Cited by 267
Chang, L.-J., Dowd, K. A., Mendoza, F. H., Saunders, J. G., Sitar, S., Plummer, S. H., Yamshchikov, G. V., Sarwar, U. N., Hu, Z., Enama, M. E., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61185-5 · Cited by 257
Self-citationGilman, M. S. A., Castellanos, C. A., Chen, M., Ngwuta, J. O., Goodwin, E. C., Moin, S. M., Más, V., Melero, J. A., Wright, P. F., Graham, B. S., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaj1879 · Cited by 238
Self-citationSwanstrom, J., Plante, J. A., Plante, K. S., Young, E., McGowan, E., Gallichotte, E. N., Widman, D. G., Heise, M. T., de Silva, A. M., & Baric, R. S. (2016) · mBio · doi:10.1128/mbio.01123-16 · Cited by 237
Murphy, B. R., & Walsh, E. E. (1988) · Journal of Clinical Microbiology · doi:10.1128/jcm.26.8.1595-1597.1988 · Cited by 228
Sullivan, N. J., Hensley, L. E., Asiedu, C. K., Geisbert, T. W., Stanley, D. A., Johnson, J. C., Honko, A. N., Olinger, G. G., Bailey, M., Geisbert, J. B., et al. (2011) · Nature Medicine · doi:10.1038/nm.2447 · Cited by 225
RECOVERY FROM INFANTS WITH RESPIRATORY ILLNESS OF A VIRUS RELATED TO CHIMPANZEE CORYZA AGENT (CCA)
Chanock, R. M., & Finberg, L. (1957) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a119902 · Cited by 208
Murphy, B. R., Alling, D. W., Snyder, M. H., Walsh, E. E., Prince, G. A., Chanock, R. M., Hemming, V. G., Rodriguez, W. J., Kim, H. W., & Graham, B. S. (1986) · Journal of Clinical Microbiology · doi:10.1128/jcm.24.5.894-898.1986 · Cited by 197
Self-citationJohnson, T. R., Johnson, J. E., Roberts, S. R., Wertz, G. W., Parker, R. A., & Graham, B. S. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.2871-2880.1998 · Cited by 191
Self-citationStructural basis of respiratory syncytial virus neutralization by motavizumab
McLellan, J. S., Chen, M., Kim, A., Yang, Y., Graham, B. S., & Kwong, P. D. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1723 · Cited by 182
Self-citationIterative structure-based improvement of a fusion-glycoprotein vaccine against RSV
Joyce, M. G., Zhang, B., Ou, L., Chen, M., Chuang, G., Druz, A., Kong, W., Lai, Y., Rundlet, E. J., Tsybovsky, Y., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3267 · Cited by 167
Self-citationStructure-based antigen design: a strategy for next generation vaccines
Dormitzer, P. R., Ulmer, J. B., & Rappuoli, R. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.08.002 · Cited by 166
Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus
Killikelly, A. M., Kanekiyo, M., & Graham, B. S. (2016) · Scientific Reports · doi:10.1038/srep34108 · Cited by 151
Self-citationGoodwin, E. C., Gilman, M. S. A., Wrapp, D., Chen, M., Ngwuta, J. O., Moin, S. M., Bai, P., Sivasubramanian, A., Connor, R. I., Wright, P. F., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.01.005 · Cited by 150
Self-citationStructural vaccinology starts to deliver
Dormitzer, P. R., Grandi, G., & Rappuoli, R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2893 · Cited by 143
Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein
Battles, M. B., Más, V., Olmedillas, E., Cano, O., Vázquez, M., Laura, R., Melero, J. A., & McLellan, J. S. (2017) · Nature Communications · doi:10.1038/s41467-017-01708-9 · Cited by 122
Self-citationRespiratory Syncytial Virus Infection in Adult Populations
Walsh, E. E., & Falsey, A. R. (2012) · Infectious Disorders - Drug Targets · doi:10.2174/187152612800100116 · Cited by 111
Mousa, J. J., Kose, N., Matta, P., Gilchuk, P., & Crowe, J. E. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.271 · Cited by 111
Structure-based energetics of protein interfaces guides foot-and-mouth disease virus vaccine design
Kotecha, A., Seago, J. E., Scott, K. A., Burman, A., Loureiro, S., Ren, J., Porta, C., Ginn, H. M., Jackson, T., Pérez-Martín, E., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3096 · Cited by 110
Chackerian, B., Durfee, M. R., & Schiller, J. T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5816 · Cited by 105
McLellan, J. S., Correia, B. E., Chen, M., Yang, Y., Graham, B. S., Schief, W. R., & Kwong, P. D. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.04.044 · Cited by 105
Self-citationStobart, C. C., Rostad, C. A., Ke, Z., Dillard, R. S., Hampton, C. M., Strauss, J. D., Yi, H. L., Hotard, A. L., Meng, J., Pickles, R. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13916 · Cited by 105
Self-citationAdvances in antiviral vaccine development
Graham, B. S. (2013) · Immunological Reviews · doi:10.1111/imr.12098 · Cited by 103
Self-citationDowd, K. A., Mukherjee, S., Kuhn, R. J., & Pierson, T. C. (2014) · Journal of Virology · doi:10.1128/jvi.01140-14 · Cited by 94
Influences on Trimerization and Aggregation of Soluble, Cleaved HIV-1 SOSIP Envelope Glycoprotein
Klasse, P. J., Depetris, R. S., Pejchal, R., Julien, J., Khayat, R., Lee, J. H., Marozsan, A. J., Cupo, A., Cocco, N., Korzun, J., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01226-13 · Cited by 90
Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens
Georgiev, I. S., Joyce, M. G., Chen, R. E., Leung, K., McKee, K., Druz, A., Galen, J. G. V., Kanekiyo, M., Tsybovsky, Y., Yang, E. S., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00192 · Cited by 90
Self-citationJohnson, T. R., McLellan, J. S., & Graham, B. S. (2011) · Journal of Virology · doi:10.1128/jvi.06096-11 · Cited by 86
Self-citationChallenges and Opportunities for Respiratory Syncytial Virus Vaccines
Graham, B. S., & Anderson, L. J. (2013) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-38919-1_20 · Cited by 79
Self-citationLiang, B., Surman, S. R., Amaro-Carambot, E., Kabatova, B., Mackow, N., Lingemann, M., Yang, L., McLellan, J. S., Graham, B. S., Kwong, P. D., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01373-15 · Cited by 71
Self-citationRespiratory Syncytial Virus Mechanisms to Interfere with Type 1 Interferons
Barik, S. (2013) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-38919-1_9 · Cited by 67
Vaccines that stimulate T cell immunity to HIV-1: the next step
McMichael, A. J., & Koff, W. C. (2014) · Nature Immunology · doi:10.1038/ni.2844 · Cited by 66
Widjojoatmodjo, M. N., Bogaert, L., Meek, B., Zahn, R. C., Vellinga, J., Custers, J. H. H. V., Serroyen, J., Radošević, K., & Schuitemaker, H. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.056 · Cited by 58
Schmaljohn, A. L. (2013) · Current HIV Research · doi:10.2174/1570162x113116660057 · Cited by 51
A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus
Stewart-Jones, G. B. E., Thomas, P. V., Chen, M., Druz, A., Joyce, M. G., Kong, W., Sastry, M., Soto, C. S., Yang, Y., Zhang, B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128779 · Cited by 49
Self-citationLópez, J. A., Andreu, D., Carreño, C., Whyte, P., Taylor, G., & Melero, J. A. (1993) · Journal of General Virology · doi:10.1099/0022-1317-74-12-2567 · Cited by 49
Protein crystallography and infectious diseases
Verlinde, C. L. M. J., Merritt, E. A., van den Akker, F., Kim, H., Feil, I., Delboni, L. F., Mande, S. C., Sarfaty, S., Pétra, P. H., & Hol, W. G. J. (1994) · Protein Science · doi:10.1002/pro.5560031006 · Cited by 45
SAT2 Foot-and-Mouth Disease Virus Structurally Modified for Increased Thermostability
Scott, K. A., Kotecha, A., Seago, J. E., Ren, J., Fry, E. E., Stuart, D. I., Charleston, B., & Maree, F. F. (2017) · Journal of Virology · doi:10.1128/jvi.02312-16 · Cited by 40
Malaria vaccine based on self-assembling protein nanoparticles
Burkhard, P., & Lanar, D. E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1096781 · Cited by 40
Opportunities to Exploit Non-Neutralizing HIV-Specific Antibody Activity
Ackerman, M. E., & Alter, G. (2013) · Current HIV Research · doi:10.2174/1570162x113116660058 · Cited by 37
Cullen, L. M., Blanco, J. C. G., & Morrison, T. G. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0705-8 · Cited by 35
RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine
Hervé, P., Deloizy, C., Descamps, D., Rameix‐Welti, M., Fix, J., McLellan, J. S., Eléouët, J., & Riffault, S. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.08.006 · Cited by 31
Self-citationStructure-based design of chimeric antigens for multivalent protein vaccines
Hollingshead, S., Jongerius, I., Exley, R. M., Johnson, S., Lea, S. M., & Tang, C. M. (2018) · Nature Communications · doi:10.1038/s41467-018-03146-7 · Cited by 31
Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site
Georgiev, I. S., Joyce, M. G., Zhou, T., & Kwong, P. D. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328363a90e · Cited by 31
Liu, X., Liang, B., Ngwuta, J. O., Liu, X., Surman, S. R., Lingemann, M., Kwong, P. D., Graham, B. S., Collins, P. L., & Munir, S. (2017) · Journal of Virology · doi:10.1128/jvi.01101-17 · Cited by 17
Self-citationStructure of the apo anti-influenza CH65 Fab
Lee, P. S., Arnell, A., & Wilson, I. A. (2015) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x14027599 · Cited by 4
Research works printed but not linked: 5
- Chanock R, 1957, Am. J. Hyg., 66, 291
- Chanock R, 1957, Am. J. Hyg., 66, 281
- Graham BS, 2013, Curr. Top Microbiol. Immunol., 372, 391
- Glezen WP, 1986, Am. J. Dis. Child, 140, 543
- Barik S, 2013, Curr. Top. Microbiol. Immunol., 372, 173
Cited by
Sorted by citations
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Self-citationSARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationEvaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066
Self-citationEfficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults
Wilson, E. M. P., Goswami, J., Baqui, A. H., Doreski, P. A., Marc, G. P., Zaman, K., Monroy, J., Duncan, C. J. A., Ujiie, M., Rämet, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307079 · Cited by 544
Duan, L., Zheng, Q., Zhang, H., Niu, Y., Lou, Y., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576622 · Cited by 417
Metadata
- Authors
- Graham, B. S., Gilman, M. S. A., & McLellan, J. S.
- Affiliations
- National Institutes of Health (US)
- The University of Texas at Austin (US)
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 2019-01-27
- Volume
- 70
- Issue
- 1
- Pages
- 91-104
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- PMC
- PMC6936610
- OpenAlex
- W2913893387
- Cited by
- 234
- References
- 94
- Citations by year
- 2026: 23 · 2025: 28 · 2024: 40 · 2023: 38 · 2022: 35 · 2021: 41 · 2020: 25 · 2019: 4
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annual Review of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI127521)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- structure-based vaccine design, antigen design, HIV-1 vaccine, respiratory syncytial virus, neutralizing antibodies, monoclonal antibodies, nanoparticle self-assembly, viral surface proteins, class I fusion proteins, emerging pathogens
- MeSH terms
- Animals, Antibodies, Monoclonal, B-Lymphocytes, Humans, Respiratory Syncytial Viruses, Sensitivity and Specificity, Structure-Activity Relationship, Vaccines, Synthetic, Viral Fusion Proteins, Viral Vaccines, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
